<!DOCTYPE html>
<html lang="en">

  <head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Chronic Coronary Syndromes: A Comprehensive Review</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/js/all.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/three.js/r128/three.min.js"></script>
    <script src="https://cdn.jsdelivr.net/npm/vanta@latest/dist/vanta.net.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Tiempos+Headline:wght@400;700&family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <style>
        :root {
            --primary: #1e40af;
            --secondary: #64748b;
            --accent: #0ea5e9;
            --neutral: #f8fafc;
            --base-100: #ffffff;
            --base-content: #1e293b;
        }
        
        body {
            font-family: 'Inter', sans-serif;
            color: var(--base-content);
            line-height: 1.6;
        }
        
        .hero-title {
            font-family: 'Tiempos Headline', serif;
            font-weight: 700;
            font-style: italic;
        }
        
        .section-title {
            font-family: 'Tiempos Headline', serif;
            font-weight: 700;
        }
        
        .vanta-bg {
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            z-index: -1;
        }
        
        .gradient-overlay {
            background: linear-gradient(135deg, rgba(30, 64, 175, 0.9) 0%, rgba(14, 165, 233, 0.7) 100%);
        }
        
        .toc-fixed {
            position: fixed;
            top: 0;
            left: 0;
            width: 280px;
            height: 100vh;
            background: linear-gradient(135deg, #1e40af 0%, #3b82f6 100%); /* Adjusted to match pediatric myocarditis */
            z-index: 1000;
            padding: 2rem 1.5rem;
            overflow-y: auto;
            transition: transform 0.3s ease;
        }
        
        .main-content { /* Renamed from .content-wrapper to .main-content for consistency with original CCS */
            margin-left: 280px;
            min-height: 100vh;
            transition: margin-left 0.3s ease;
        }
        
        .citation {
            display: inline-block;
            background: var(--accent);
            color: white;
            padding: 0.125rem 0.375rem;
            border-radius: 0.25rem;
            font-size: 0.75rem;
            font-weight: 500;
            text-decoration: none;
            margin-left: 0.25rem;
            transition: all 0.2s;
        }
        
        .citation:hover {
            background: var(--primary);
            transform: translateY(-1px);
        }
        
        .bento-grid {
            display: grid;
            grid-template-columns: 2fr 1fr;
            gap: 2rem;
            align-items: start;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
            border-left: 4px solid var(--accent);
            padding: 1.5rem;
            border-radius: 0.5rem;
            margin: 1.5rem 0;
        }
        
        .evidence-level {
            display: inline-block;
            padding: 0.25rem 0.75rem;
            border-radius: 1rem;
            font-size: 0.875rem;
            font-weight: 600;
            margin-left: 0.5rem;
        }
        
        .class-i {
            background: #dcfce7;
            color: #166534;
        }
        
        .class-ii {
            background: #fef3c7;
            color: #92400e;
        }
        
        .level-a {
            border: 2px solid #166534;
        }
        
        .level-b {
            border: 2px solid #92400e;
        }

        /* Styles from pediatric myocarditis for TOC links and responsiveness */
        @media (max-width: 1024px) {
            .toc-fixed {
                transform: translateX(-100%);
                transition: transform 0.3s ease;
            }
            
            .toc-fixed.open {
                transform: translateX(0);
            }
            
            .main-content { /* Renamed for consistency */
                margin-left: 0;
            }
            
            .bento-grid {
                grid-template-columns: 1fr;
            }

            .toggle-toc { /* Ensure toggle button is visible on smaller screens */
                display: block;
            }
        }

        /* Specific TOC link styles from pediatric myocarditis */
        .toc-link {
            display: block;
            color: rgba(255, 255, 255, 0.8);
            text-decoration: none;
            padding: 0.5rem 0;
            border-left: 2px solid transparent;
            padding-left: 1rem;
            transition: all 0.2s ease;
        }
        
        .toc-link:hover,
        .toc-link.active {
            color: white;
            border-left-color: var(--accent);
            background: rgba(255, 255, 255, 0.1);
            transform: translateX(4px);
        }
        
        .toc-link.sub {
            font-size: 0.9rem;
            padding-left: 2rem;
            color: rgba(255, 255, 255, 0.7);
        }

        /* Toggle TOC Button */
        .toggle-toc {
            display: none;
            position: fixed;
            top: 1rem;
            left: 1rem;
            z-index: 1100;
            background: var(--primary);
            color: white;
            border: none;
            border-radius: 0.5rem;
            padding: 0.75rem;
            cursor: pointer;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
        }
        
        @media (max-width: 768px) {
            .hero-title {
                font-size: 2.5rem;
            }

            .text-7xl {
                font-size: 3rem;
            }

            .text-6xl {
                font-size: 2.5rem;
            }

            .text-5xl {
                font-size: 2rem;
            }

            .text-4xl {
                font-size: 1.75rem;
            }

            .text-3xl {
                font-size: 1.5rem;
            }

            .text-2xl {
                font-size: 1.25rem;
            }

            .text-xl {
                font-size: 1.125rem;
            }

            .px-8 {
                padding-left: 1rem;
                padding-right: 1rem;
            }

            .py-16 {
                padding-top: 2rem;
                padding-bottom: 2rem;
            }

            .py-12 {
                padding-top: 1.5rem;
                padding-bottom: 1.5rem;
            }

            .py-8 {
                padding-top: 1rem;
                padding-bottom: 1rem;
            }

            .py-6 {
                padding-top: 0.75rem;
                padding-bottom: 0.75rem;
            }

            .p-8 {
                padding: 1rem;
            }

            .p-6 {
                padding: 0.75rem;
            }

            .p-4 {
                padding: 0.5rem;
            }

            .m-8 {
                margin: 1rem;
            }

            .m-6 {
                margin: 0.75rem;
            }

            .m-4 {
                margin: 0.5rem;
            }

            .m-2 {
                margin: 0.25rem;
            }

            .grid-cols-3, .grid-cols-2, .lg\:grid-cols-3, .lg\:grid-cols-2, .md\:grid-cols-3, .md\:grid-cols-2 {
                grid-template-columns: 1fr;
            }

            .flex-wrap {
                flex-wrap: wrap;
            }

            .overflow-x-auto {
                overflow-x: auto;
            }

            table {
                display: block;
                overflow-x: auto;
                white-space: nowrap;
            }

            .space-y-6 > * + * {
                margin-top: 1rem;
            }

            .space-y-8 > * + * {
                margin-top: 1rem;
            }

            img {
                max-width: 100%;
                height: auto;
            }

            .prose-lg p {
                font-size: 1rem;
            }

            .prose-lg ul {
                font-size: 1rem;
            }
        }
    </style>
  </head>

  <body class="bg-neutral">
    <button class="toggle-toc" onclick="toggleTOC()">
      <i class="fas fa-bars"></i>
    </button>

    <nav class="toc-fixed" id="toc">
      <div class="mb-6">
        <h3 class="text-white font-bold text-lg mb-4">Table of Contents</h3>
        <a href="#definition" class="toc-link">1. Definition & Classification</a>
        <a href="#definition-esc" class="toc-link sub">1.1 ESC 2024 Definition</a>
        <a href="#definition-spectrum" class="toc-link sub">1.2 Clinical Spectrum</a>
        <a href="#pathophysiology" class="toc-link">2. Pathophysiology</a>
        <a href="#pathophysiology-epicardial" class="toc-link sub">2.1 Epicardial CAD</a>
        <a href="#pathophysiology-endothelial" class="toc-link sub">2.2 Endothelial Dysfunction</a>
        <a href="#pathophysiology-microvascular" class="toc-link sub">2.3 Microvascular Dysfunction</a>
        <a href="#pathophysiology-vasospasm" class="toc-link sub">2.4 Coronary Vasospasm & Plaque Vulnerability</a>
        <a href="#diagnosis" class="toc-link">3. Diagnosis</a>
        <a href="#diagnosis-step1" class="toc-link sub">3.1 General Clinical Examination</a>
        <a href="#diagnosis-step2" class="toc-link sub">3.2 Pre-test Clinical Likelihood</a>
        <a href="#diagnosis-step3" class="toc-link sub">3.3 Confirming the Diagnosis</a>
        <a href="#diagnosis-step4" class="toc-link sub">3.4 Initial Therapy & Follow-up</a>
        <a href="#management" class="toc-link">4. Management & Treatment</a>
        <a href="#management-gdmt" class="toc-link sub">4.1 Guideline-Directed Medical Therapy</a>
        <a href="#management-lifestyle" class="toc-link sub">4.1.1 Lifestyle Modifications</a>
        <a href="#management-antiplatelet" class="toc-link sub">4.1.2 Antiplatelet Therapy</a>
        <a href="#management-lipid" class="toc-link sub">4.1.3 Lipid-Lowering Therapy</a>
        <a href="#management-novel" class="toc-link sub">4.2 Novel Therapeutic Agents</a>
        <a href="#management-revasc" class="toc-link sub">4.3 Revascularization Strategies</a>
        <a href="#trials" class="toc-link">5. Recent Clinical Trials</a>
        <a href="#trials-medical" class="toc-link sub">5.1 Trials Informing Medical Therapy</a>
        <a href="#trials-revasc" class="toc-link sub">5.2 Trials Informing Revascularization</a>
        <a href="#trials-anoca" class="toc-link sub">5.3 ANOCA/INOCA Trials</a>
        <a href="#tables" class="toc-link">6. Quick Reference Tables</a>
        <a href="#tables-comparison" class="toc-link sub">6.1 ESC vs ACC/AHA Comparison</a>
        <a href="#tables-trials" class="toc-link sub">6.2 Summary of Recent Trials</a>
        <a href="#tables-diagnostic" class="toc-link sub">6.3 ESC 2024 Diagnostic Approach</a>
      </div>
    </nav>

    <div class="main-content">
      <section class="relative min-h-screen flex items-center">
        <div id="vanta-bg" class="vanta-bg"></div>
        <div class="gradient-overlay absolute inset-0"></div>

        <div class="relative z-10 max-w-7xl mx-auto px-8 py-16">
          <div class="bento-grid">
            <div class="space-y-8">
              <div class="space-y-4">
                <h1 class="hero-title text-7xl text-white leading-tight">
                  Chronic Coronary
                  <br>
                  <span class="text-cyan-200">Syndromes</span>
                </h1>
                <p class="text-xl text-blue-100 max-w-2xl">
                  A Comprehensive Review for Cardiology Board Review (July 2025)
                </p>
              </div>

              <div class="flex flex-wrap gap-4">
                <span class="bg-white/20 backdrop-blur-sm px-4 py-2 rounded-full text-white text-sm font-medium">
                  <i class="fas fa-heart-pulse mr-2"></i>ESC 2024 Guidelines
                </span>
                <span class="bg-white/20 backdrop-blur-sm px-4 py-2 rounded-full text-white text-sm font-medium">
                  <i class="fas fa-stethoscope mr-2"></i>ACC/AHA 2023 Updates
                </span>
              </div>
            </div>

            <div class="bg-white/10 backdrop-blur-sm rounded-2xl p-8 space-y-6">
              <h3 class="text-2xl font-bold text-white mb-4">Key Highlights</h3>
              <div class="space-y-4">
                <div class="flex items-start space-x-3">
                  <i class="fas fa-check-circle text-cyan-300 mt-1"></i>
                  <p class="text-blue-100">New 4-step diagnostic approach with RF-CL model</p>
                </div>
                <div class="flex items-start space-x-3">
                  <i class="fas fa-pills text-cyan-300 mt-1"></i>
                  <p class="text-blue-100">Clopidogrel monotherapy now Class IA recommendation</p>
                </div>
                <div class="flex items-start space-x-3">
                  <i class="fas fa-microscope text-cyan-300 mt-1"></i>
                  <p class="text-blue-100">ANOCA/INOCA emphasis with specific management</p>
                </div>
                <div class="flex items-start space-x-3">
                  <i class="fas fa-chart-line text-cyan-300 mt-1"></i>
                  <p class="text-blue-100">LDL-C target <1.4 mmol/L with≥50% reduction</p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <section id="definition" class="py-16 bg-white">
        <div class="max-w-6xl mx-auto px-8">
          <h2 class="section-title text-4xl text-primary mb-8">1. Definition and Classification of Chronic Coronary Syndromes</h2>

          <div id="definition-esc" class="prose prose-lg max-w-none mb-12">
            <h3 class="section-title text-2xl text-secondary mb-4">1.1 ESC 2024 Definition</h3>
            <p class="text-lg mb-6">
              The <strong>2024 European Society of Cardiology (ESC) Guidelines</strong> define Chronic Coronary Syndromes (CCS) as a range of clinical presentations arising from <strong>structural and/or functional alterations related to chronic diseases of the coronary arteries and/or microcirculation</strong>
              <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11840264/" class="citation" target="_blank">5</a>
              <a href="https://conferences.medicom-publishers.com/specialisation/cardiology/esc-2024/guidelines-for-the-management-of-chronic-coronary-syndromes/" class="citation" target="_blank">380</a>.
              These alterations lead to a <strong>temporary, reversible mismatch between myocardial oxygen demand and blood supply</strong>, resulting in myocardial hypoperfusion and ischemia.
            </p>

            <div class="highlight-box">
              <h4 class="font-bold text-lg mb-3">Key Evolution from 2019 Guidelines</h4>
              <ul class="space-y-2">
                <li>• Expanded pathophysiological concepts to include microvascular disease and vasospastic disorders</li>
                <li>• Alignment with 2023 AHA/ACC terminology shift to "chronic coronary disease (CCD)"</li>
                <li>• Emphasis on stepwise diagnostic and therapeutic approach</li>
              </ul>
            </div>
          </div>

          <div id="definition-spectrum" class="mb-12">
            <h3 class="section-title text-2xl text-secondary mb-4 mt-12">1.2 Clinical Spectrum and Presentations</h3>

            <div class="grid md:grid-cols-2 gap-6 mt-8">
              <div class="bg-slate-50 p-6 rounded-lg border-l-4 border-primary">
                <h4 class="font-bold text-lg mb-3">Five Key Patient Populations</h4>
                <ol class="space-y-3 text-sm">
                  <li><strong>1.</strong> Nonacute patients post-ACS or revascularization</li>
                  <li><strong>2.</strong> Patients with heart failure of ischemic/cardiometabolic origin</li>
                  <li><strong>3.</strong> Symptomatic patients with reproducible stress-induced angina</li>
                  <li><strong>4.</strong> Patients with ANOCA/INOCA (angina/ischemia without obstructive CAD)</li>
                  <li><strong>5.</strong> Asymptomatic patients with abnormal test results</li>
                </ol>
              </div>

              <div class="bg-blue-50 p-6 rounded-lg">
                <h4 class="font-bold text-lg mb-3 flex items-center">
                  <i class="fas fa-exclamation-triangle text-amber-500 mr-2"></i>
                  ANOCA/INOCA Emphasis
                </h4>
                <p class="text-sm mb-3">
                  <strong>Angina with No Obstructive Coronary Arteries (ANOCA)</strong> and <strong>Ischemia with No Obstructive Coronary Arteries (INOCA)</strong> represent significant advancements in understanding CCS pathophysiology.
                </p>
                <p class="text-sm text-secondary">
                  The 2024 ESC guidelines place increased emphasis on diagnosing and managing these conditions
                  <a href="https://www.revespcardiol.org/en-comments-on-esc-2024-guidelines-articulo-S188558572400313X" class="citation" target="_blank">416</a>.
                </p>
              </div>
            </div>
          </div>
        </div>
      </section>

      <section id="pathophysiology" class="py-16 bg-slate-50">
        <div class="max-w-6xl mx-auto px-8">
          <h2 class="section-title text-4xl text-primary mb-8">2. Pathophysiology of Chronic Coronary Syndromes</h2>

          <p class="text-lg text-secondary mb-8">
            The pathophysiology of CCS is complex and multifactorial, involving both structural and functional abnormalities in epicardial coronary arteries and coronary microcirculation
            <a href="https://conferences.medicom-publishers.com/specialisation/cardiology/esc-2024/guidelines-for-the-management-of-chronic-coronary-syndromes/" class="citation" target="_blank">404</a>.
          </p>

          <div class="grid lg:grid-cols-3 gap-8">
            <div id="pathophysiology-epicardial" class="bg-white rounded-xl p-6 shadow-sm">
              <div class="flex items-center mb-4">
                <i class="fas fa-artery text-red-500 text-2xl mr-3"></i>
                <h3 class="section-title text-xl">2.1 Epicardial CAD</h3>
              </div>
              <p class="text-sm text-secondary mb-4">
                Characterized by atherosclerotic plaque accumulation in large coronary arteries, leading to luminal narrowing and reduced blood flow during increased myocardial demand.
              </p>
              <div class="space-y-2 text-sm">
                <div class="flex items-center">
                  <i class="fas fa-circle text-red-400 text-xs mr-2"></i>
                  <span>Chronic inflammatory process</span>
                </div>
                <div class="flex items-center">
                  <i class="fas fa-circle text-red-400 text-xs mr-2"></i>
                  <span>Lipid accumulation & macrophage infiltration</span>
                </div>
                <div class="flex items-center">
                  <i class="fas fa-circle text-red-400 text-xs mr-2"></i>
                  <span>Vulnerable plaque formation</span>
                </div>
              </div>
            </div>

            <div id="pathophysiology-endothelial" class="bg-white rounded-xl p-6 shadow-sm">
              <div class="flex items-center mb-4">
                <i class="fas fa-microscope text-blue-500 text-2xl mr-3"></i>
                <h3 class="section-title text-xl">2.2 Endothelial Dysfunction</h3>
              </div>
              <p class="text-sm text-secondary mb-4">
                Critical early event in atherosclerosis pathogenesis, particularly in ANOCA/INOCA patients, involving imbalance between vasodilating and vasoconstricting factors.
              </p>
              <div class="bg-blue-50 p-3 rounded text-xs">
                <strong>Diagnostic Gold Standard:</strong> Acetylcholine provocation testing to assess endothelial function
                <a href="https://pubmed.ncbi.nlm.nih.gov/40122215/" class="citation" target="_blank">385</a>
              </div>
            </div>

            <div id="pathophysiology-microvascular" class="bg-white rounded-xl p-6 shadow-sm">
              <div class="flex items-center mb-4">
                <i class="fas fa-project-diagram text-purple-500 text-2xl mr-3"></i>
                <h3 class="section-title text-xl">2.3 Microvascular Dysfunction</h3>
              </div>
              <p class="text-sm text-secondary mb-4">
                Structural/functional abnormalities in pre-arterioles and arterioles (&lt;500 µm) impairing myocardial blood flow regulation.
              </p>
              <div class="space-y-2 text-sm">
                <div class="bg-purple-50 p-2 rounded">
                  <strong>Coronary Flow Reserve (CFR):</strong> &lt;2.0-2.5 suggests CMD
                </div>
                <div class="bg-purple-50 p-2 rounded">
                  <strong>Index of Microcirculatory Resistance (IMR):</strong> Elevated values indicate dysfunction
                </div>
              </div>
            </div>
          </div>

          <div id="pathophysiology-vasospasm" class="mt-12">
            <div class="highlight-box">
              <h4 class="font-bold text-lg mb-4">
                <i class="fas fa-heart-pulse mr-2 text-primary"></i>
                2.4 Coronary Vasospasm and Plaque Vulnerability
              </h4>
              <div class="grid md:grid-cols-2 gap-6">
                <div>
                  <h5 class="font-semibold mb-2">Vasospastic Angina</h5>
                  <p class="text-sm text-secondary mb-3">
                    Transient, intense constriction of epicardial coronary artery segments, potentially leading to complete occlusion and myocardial ischemia.
                  </p>
                  <p class="text-xs text-secondary">
                    Associated with hyperreactivity of vascular smooth muscle cells and endothelial dysfunction
                    <a href="https://www.ecrjournal.com/articles/what-new-2024-european-society-cardiology-congress-management-chronic-coronary-syndromes?language_content_entity=en" class="citation" target="_blank">388</a>.
                  </p>
                </div>
                <div>
                  <h5 class="font-semibold mb-2">Plaque Vulnerability</h5>
                  <p class="text-sm text-secondary mb-3">
                    Vulnerable plaques characterized by thin fibrous cap, large lipid-rich necrotic core, positive remodeling, and significant inflammation.
                  </p>
                  <p class="text-xs text-secondary">
                    Many acute events arise from rupture of previously non-obstructive plaques
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3111722/" class="citation" target="_blank">391</a>.
                  </p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <section id="diagnosis" class="py-16 bg-white">
        <div class="max-w-6xl mx-auto px-8">
          <h2 class="section-title text-4xl text-primary mb-8">3. Diagnosis of Chronic Coronary Syndromes</h2>

          <h3 class="section-title text-2xl text-secondary mb-6">ESC 2024: Four-Step Diagnostic Approach</h3>

          <div class="space-y-8">
            <div id="diagnosis-step1" class="bg-gradient-to-r from-blue-50 to-cyan-50 p-6 rounded-xl border-l-4 border-primary">
              <div class="flex items-center mb-4">
                <div class="bg-primary text-white rounded-full w-8 h-8 flex items-center justify-center font-bold mr-4">1</div>
                <h4 class="section-title text-xl">3.1 General Clinical Examination</h4>
              </div>
              <div class="grid md:grid-cols-2 gap-6">
                <div>
                  <h5 class="font-semibold mb-2">Comprehensive Assessment</h5>
                  <ul class="text-sm space-y-1">
                    <li>• Detailed symptom history (beyond typical/atypical classification)</li>
                    <li>• Differential diagnosis consideration</li>
                    <li>• Physical examination for CVD signs</li>
                  </ul>
                </div>
                <div>
                  <h5 class="font-semibold mb-2">Basic Testing</h5>
                  <ul class="text-sm space-y-1">
                    <li>• 12-lead resting ECG</li>
                    <li>• Blood tests (lipid profile, glucose, renal function)</li>
                    <li>• hs-CRP/fibrinogen (Class IIa, Level B)</li>
                  </ul>
                </div>
              </div>
            </div>

            <div id="diagnosis-step2" class="bg-gradient-to-r from-purple-50 to-pink-50 p-6 rounded-xl border-l-4 border-purple-500">
              <div class="flex items-center mb-4">
                <div class="bg-purple-500 text-white rounded-full w-8 h-8 flex items-center justify-center font-bold mr-4">2</div>
                <h4 class="section-title text-xl">3.2 Pre-test Clinical Likelihood Assessment</h4>
              </div>
              <div class="grid md:grid-cols-2 gap-6">
                <div>
                  <h5 class="font-semibold mb-2">Risk Factor-Weighted Clinical Likelihood (RF-CL) Model</h5>
                  <p class="text-sm text-secondary mb-3">
                    <strong class="evidence-level class-i">Class I, Level B</strong>
                    Incorporates age, sex, symptom characteristics, and cardiovascular risk factors
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11840264/" class="citation" target="_blank">380</a>.
                  </p>
                  <div class="bg-purple-100 p-3 rounded text-xs">
                    <strong>Key Impact:</strong> Tripled the number of individuals classified as very low likelihood (≤5%), reducing unnecessary testing
                  </div>
                </div>
                <div>
                  <h5 class="font-semibold mb-2">Additional Evaluations</h5>
                  <ul class="text-sm space-y-1">
                    <li>• Transthoracic Echocardiography (TTE)</li>
                    <li>• Exercise ECG testing (selected patients)</li>
                    <li>• Ambulatory ECG monitoring (suspected vasospasm)</li>
                  </ul>
                </div>
              </div>
            </div>

            <div id="diagnosis-step3" class="bg-gradient-to-r from-green-50 to-emerald-50 p-6 rounded-xl border-l-4 border-green-500">
              <div class="flex items-center mb-4">
                <div class="bg-green-500 text-white rounded-full w-8 h-8 flex items-center justify-center font-bold mr-4">3</div>
                <h4 class="section-title text-xl">3.3 Confirming the Diagnosis</h4>
              </div>
              <div class="grid lg:grid-cols-3 gap-6">
                <div class="bg-white p-4 rounded-lg shadow-sm">
                  <h5 class="font-semibold mb-3 text-green-700">Anatomical Imaging</h5>
                  <p class="text-sm mb-2"><strong>CCTA preferred</strong> for low-intermediate PCL (>5% to ≤50%)</p>
                  <p class="text-xs text-secondary">High negative predictive value, assesses plaque burden and high-risk features</p>
                </div>
                <div class="bg-white p-4 rounded-lg shadow-sm">
                  <h5 class="font-semibold mb-3 text-green-700">Functional Imaging</h5>
                  <ul class="text-sm space-y-1">
                    <li>• Stress Echocardiography</li>
                    <li>• Myocardial Perfusion SPECT/PET</li>
                    <li>• Stress Cardiac MRI</li>
                  </ul>
                </div>
                <div class="bg-white p-4 rounded-lg shadow-sm">
                  <h5 class="font-semibold mb-3 text-green-700">Invasive Tests</h5>
                  <ul class="text-sm space-y-1">
                    <li>• Invasive Coronary Angiography (ICA)</li>
                    <li>• Functional Assessment (FFR, iFR)</li>
                    <li>• Coronary Function Testing</li>
                  </ul>
                </div>
              </div>
            </div>

            <div id="diagnosis-step4" class="bg-gradient-to-r from-amber-50 to-orange-50 p-6 rounded-xl border-l-4 border-amber-500">
              <div class="flex items-center mb-4">
                <div class="bg-amber-500 text-white rounded-full w-8 h-8 flex items-center justify-center font-bold mr-4">4</div>
                <h4 class="section-title text-xl">3.4 Initial Therapy and Follow-up</h4>
              </div>
              <div class="grid md:grid-cols-2 gap-6">
                <div>
                  <h5 class="font-semibold mb-2">Initial Therapy</h5>
                  <p class="text-sm">Intensification of lifestyle modifications, risk factor management, and guideline-directed medical therapy (GDMT)</p>
                </div>
                <div>
                  <h5 class="font-semibold mb-2">Follow-up Considerations</h5>
                  <p class="text-sm">Repeat revascularization for persistent symptoms despite optimized GDMT, functional testing for uncertain symptoms</p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <section id="management" class="py-16 bg-slate-50">
        <div class="max-w-6xl mx-auto px-8">
          <h2 class="section-title text-4xl text-primary mb-8">4. Management of Chronic Coronary Syndromes</h2>

          <div id="management-gdmt">
            <h3 class="section-title text-2xl text-secondary mb-8">4.1 Guideline-Directed Medical Therapy (GDMT)</h3>

            <div class="grid lg:grid-cols-2 gap-8 mb-12">
              <div id="management-lifestyle" class="bg-white rounded-xl p-6 shadow-sm">
                <h4 class="section-title text-lg mb-4 flex items-center">
                  <i class="fas fa-heart-pulse text-red-500 mr-3"></i>
                  4.1.1 Lifestyle Modifications & Risk Factor Control
                </h4>
                <div class="space-y-4">
                  <div class="bg-red-50 p-4 rounded-lg">
                    <h5 class="font-semibold mb-2">Core Interventions</h5>
                    <ul class="text-sm space-y-1">
                      <li>• Smoking cessation programs</li>
                      <li>• Mediterranean or DASH diet</li>
                      <li>• Regular physical activity (≥150 min moderate-intensity/week)</li>
                      <li>• Weight management for overweight/obese patients</li>
                    </ul>
                  </div>
                  <div class="bg-blue-50 p-4 rounded-lg">
                    <h5 class="font-semibold mb-2">Mobile Health Interventions</h5>
                    <p class="text-sm">
                      <strong class="evidence-level class-i">Class I, Level C</strong>
                      Text messages, apps, wearable devices to improve adherence
                      <a href="https://icus-society.org/wp-content/uploads/2024/09/ESCCCS-2024-guideline7.pdf" class="citation" target="_blank">151</a>
                    </p>
                  </div>
                </div>
              </div>

              <div id="management-antiplatelet" class="bg-white rounded-xl p-6 shadow-sm">
                <h4 class="section-title text-lg mb-4 flex items-center">
                  <i class="fas fa-pills text-blue-500 mr-3"></i>
                  4.1.2 Antiplatelet Therapy
                </h4>
                <div class="space-y-4">
                  <div class="bg-blue-50 p-4 rounded-lg">
                    <h5 class="font-semibold mb-2">ESC 2024 Updates</h5>
                    <p class="text-sm mb-2">
                      <strong>Clopidogrel monotherapy (75mg daily)</strong>
                      <span class="evidence-level class-i">Class I, Level A</span>
                      for CCS patients with prior MI or remote PCI
                    </p>
                    <p class="text-xs text-secondary">
                      Supported by HOST-EXAM trial showing superiority over aspirin
                      <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11622220/" class="citation" target="_blank">131</a>
                    </p>
                  </div>
                  <div class="bg-purple-50 p-4 rounded-lg">
                    <h5 class="font-semibold mb-2">High Bleeding Risk Patients</h5>
                    <p class="text-sm">
                      Short DAPT duration (1-3 months) recommended based on Master-DAPT trial
                      <a href="https://www.ecrjournal.com/articles/what-new-2024-european-society-cardiology-congress-management-chronic-coronary-syndromes?language_content_entity=en" class="citation" target="_blank">486</a>
                    </p>
                  </div>
                </div>
              </div>
            </div>

            <div id="management-lipid" class="bg-white rounded-xl p-8 shadow-sm mb-8">
              <h4 class="section-title text-xl mb-6 flex items-center">
                <i class="fas fa-chart-line text-green-500 mr-3"></i>
                4.1.3 Lipid-Lowering Therapy
              </h4>
              <div class="grid md:grid-cols-2 gap-8">
                <div>
                  <h5 class="font-semibold mb-3">ESC 2024 Targets</h5>
                  <div class="bg-green-50 p-4 rounded-lg mb-4">
                    <p class="text-sm mb-2">
                      <strong>Primary Goal:</strong> LDL-C &lt;1.4 mmol/L (55 mg/dL) and ≥50% reduction from baseline
                    </p>
                    <p class="text-xs text-secondary">
                      <span class="evidence-level class-i">Class I, Level A</span>
                      High-intensity statins up to maximum tolerated dose
                      <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11840264/" class="citation" target="_blank">160</a>
                    </p>
                  </div>
                  <div class="space-y-2 text-sm">
                    <div class="flex items-center">
                      <i class="fas fa-arrow-right text-green-500 mr-2"></i>
                      <span>Add ezetimibe if targets not met</span>
                    </div>
                    <div class="flex items-center">
                      <i class="fas fa-arrow-right text-green-500 mr-2"></i>
                      <span>Consider PCSK9 inhibitors if still not achieved</span>
                    </div>
                    <div class="flex items-center">
                      <i class="fas fa-arrow-right text-green-500 mr-2"></i>
                      <span>Bempedoic acid for statin-intolerant patients</span>
                    </div>
                  </div>
                </div>
                <div>
                  <h5 class="font-semibold mb-3">ACC/AHA 2023 Approach</h5>
                  <div class="bg-blue-50 p-4 rounded-lg">
                    <p class="text-sm mb-2">
                      High-intensity statins recommended. If contraindicated:
                    </p>
                    <p class="text-sm">
                      Moderate-intensity statins targeting 30-49% LDL-C reduction
                      <a href="https://www.nature.com/articles/s44325-024-00006-w" class="citation" target="_blank">346</a>
                    </p>
                  </div>
                </div>
              </div>
            </div>
          </div>

          <div id="management-novel" class="bg-gradient-to-r from-cyan-50 to-blue-50 rounded-xl p-8 mb-8">
            <h4 class="section-title text-xl mb-6 flex items-center">
              <i class="fas fa-flask text-cyan-600 mr-3"></i>
              4.2 Novel Therapeutic Agents
            </h4>
            <div class="grid lg:grid-cols-3 gap-6">
              <div class="bg-white p-6 rounded-lg">
                <h5 class="font-semibold mb-3 text-cyan-700">SGLT2 Inhibitors</h5>
                <p class="text-sm mb-3">
                  <span class="evidence-level class-i">Class I, Level A</span>
                  Recommended for CCS patients with T2DM to reduce CV events
                </p>
                <div class="text-xs text-secondary space-y-1">
                  <p>• Proven CV benefits in DECLARE-TIMI 58, EMPA-REG OUTCOME</p>
                  <p>• Benefits extend beyond glucose control</p>
                </div>
              </div>

              <div class="bg-white p-6 rounded-lg">
                <h5 class="font-semibold mb-3 text-blue-700">GLP-1 Receptor Agonists</h5>
                <p class="text-sm mb-3">
                  <span class="evidence-level class-i">Class I, Level A</span> for T2DM
                  <br>
                  <span class="evidence-level class-ii">Class IIa, Level B</span> for obesity without diabetes
                </p>
                <div class="text-xs text-secondary space-y-1">
                  <p>• SELECT trial: Semaglutide reduced MACE in obese patients without diabetes</p>
                  <p>• Weight reduction and metabolic benefits</p>
                </div>
              </div>

              <div class="bg-white p-6 rounded-lg">
                <h5 class="font-semibold mb-3 text-purple-700">Colchicine</h5>
                <p class="text-sm mb-3">
                  <span class="evidence-level class-ii">Class IIb, Level A</span>
                  Low-dose colchicine (0.5mg daily) considered in CCS patients with atherosclerotic CAD
                </p>
                <div class="text-xs text-secondary space-y-1">
                  <p>• LoDoCo2 trial: 31% RRR in composite endpoint</p>
                  <p>• Targets residual inflammatory risk</p>
                </div>
              </div>
            </div>
          </div>

          <div id="management-revasc" class="bg-white rounded-xl p-8">
            <h4 class="section-title text-xl mb-6 flex items-center">
              <i class="fas fa-procedures text-red-600 mr-3"></i>
              4.3 Revascularization Strategies
            </h4>
            <div class="grid lg:grid-cols-2 gap-8">
              <div class="space-y-4">
                <h5 class="font-semibold text-lg">Percutaneous Coronary Intervention (PCI)</h5>
                <div class="bg-red-50 p-4 rounded-lg">
                  <p class="text-sm mb-2">
                    <strong>Indication:</strong> Symptomatic CCS patients with functionally significant obstructive CAD (FFR ≤0.80) who remain symptomatic despite GDMT
                  </p>
                  <p class="text-xs text-secondary">
                    ORBITA-2 trial reinforced PCI efficacy for symptom relief
                    <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11622220/" class="citation" target="_blank">355</a>
                  </p>
                </div>
                <div class="bg-amber-50 p-3 rounded">
                  <p class="text-sm">
                    <strong>Intracoronary Imaging Guidance:</strong>
                    <span class="evidence-level class-i">Class I</span>
                    for complex lesions (left main, bifurcations, long lesions)
                  </p>
                </div>
              </div>
              <div class="space-y-4">
                <h5 class="font-semibold text-lg">Coronary Artery Bypass Grafting (CABG)</h5>
                <div class="bg-blue-50 p-4 rounded-lg">
                  <p class="text-sm mb-2">
                    <strong>Preferred for:</strong> Complex multivessel disease, left main disease, diabetes, LV dysfunction
                  </p>
                  <p class="text-xs text-secondary">
                    STICH trial: CABG superior to medical therapy in ischemic cardiomyopathy with LVEF ≤35%
                  </p>
                </div>
                <div class="bg-green-50 p-3 rounded">
                  <p class="text-sm">
                    <strong>Heart Team Approach:</strong>
                    <span class="evidence-level class-i">Class I, Level C</span>
                    Multidisciplinary decision-making essential
                  </p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <div class="section-divider"></div>

      <section id="trials" class="py-16 bg-white">
        <div class="max-w-6xl mx-auto px-8">
          <h2 class="section-title text-4xl text-primary mb-8">5. Recent Clinical Trials and Evolving Evidence (2022-2025)</h2>

          <div class="grid lg:grid-cols-2 gap-8">
            <div id="trials-medical" class="space-y-6">
              <h3 class="section-title text-xl text-secondary mb-4">5.1 Trials Informing Medical Therapy</h3>

              <div class="bg-gradient-to-r from-green-50 to-emerald-50 p-6 rounded-xl border-l-4 border-green-500">
                <h4 class="font-bold mb-3 flex items-center">
                  <i class="fas fa-pills text-green-600 mr-2"></i>
                  Antiplatelet Therapy
                </h4>
                <div class="space-y-4">
                  <div class="bg-white p-4 rounded-lg">
                    <h5 class="font-semibold text-sm mb-2">HOST-EXAM Trial</h5>
                    <p class="text-xs text-secondary mb-2">Clopidogrel vs Aspirin monotherapy post-PCI</p>
                    <p class="text-sm">Clopidogrel superior in reducing composite endpoint (5.7% vs 7.7%, HR 0.73)</p>
                  </div>
                  <div class="bg-white p-4 rounded-lg">
                    <h5 class="font-semibold text-sm mb-2">Master-DAPT Trial</h5>
                    <p class="text-xs text-secondary mb-2">Abbreviated vs Standard DAPT in HBR patients</p>
                    <p class="text-sm">1-month DAPT non-inferior for net adverse clinical events, superior for bleeding</p>
                  </div>
                </div>
              </div>

              <div class="bg-gradient-to-r from-blue-50 to-cyan-50 p-6 rounded-xl border-l-4 border-blue-500">
                <h4 class="font-bold mb-3 flex items-center">
                  <i class="fas fa-flask text-blue-600 mr-2"></i>
                  Novel Therapeutic Agents
                </h4>
                <div class="space-y-4">
                  <div class="bg-white p-4 rounded-lg">
                    <h5 class="font-semibold text-sm mb-2">LoDoCo2 Trial</h5>
                    <p class="text-xs text-secondary mb-2">Low-dose colchicine (0.5mg) in chronic coronary disease</p>
                    <p class="text-sm">31% reduction in composite CV endpoint (HR 0.69)</p>
                  </div>
                  <div class="bg-white p-4 rounded-lg">
                    <h5 class="font-semibold text-sm mb-2">SELECT Trial</h5>
                    <p class="text-xs text-secondary mb-2">Semaglutide in overweight/obese adults with CVD, no diabetes</p>
                    <p class="text-sm">20% reduction in MACE (CV death, MI, stroke)</p>
                  </div>
                </div>
              </div>
            </div>

            <div id="trials-revasc" class="space-y-6">
              <h3 class="section-title text-xl text-secondary mb-4">5.2 Trials Informing Revascularization</h3>

              <div class="bg-gradient-to-r from-purple-50 to-pink-50 p-6 rounded-xl border-l-4 border-purple-500">
                <h4 class="font-bold mb-3 flex items-center">
                  <i class="fas fa-procedures text-purple-600 mr-2"></i>
                  PCI Optimization
                </h4>
                <div class="space-y-4">
                  <div class="bg-white p-4 rounded-lg">
                    <h5 class="font-semibold text-sm mb-2">ORBITA-2 Trial</h5>
                    <p class="text-xs text-secondary mb-2">PCI vs Sham in stable angina without antianginals</p>
                    <p class="text-sm">PCI significantly improved angina symptoms and exercise tolerance</p>
                  </div>
                  <div class="bg-white p-4 rounded-lg">
                    <h5 class="font-semibold text-sm mb-2">RENOVATE-COMPLEX-PCI</h5>
                    <p class="text-xs text-secondary mb-2">IVUS-guided vs angiography-guided PCI</p>
                    <p class="text-sm">38% reduction in composite endpoint with IVUS guidance</p>
                  </div>
                </div>
              </div>

              <div class="bg-gradient-to-r from-amber-50 to-orange-50 p-6 rounded-xl border-l-4 border-amber-500">
                <h4 class="font-bold mb-3 flex items-center">
                  <i class="fas fa-heart-pulse text-amber-600 mr-2"></i>
                  Special Populations
                </h4>
                <div class="space-y-4">
                  <div class="bg-white p-4 rounded-lg">
                    <h5 class="font-semibold text-sm mb-2">REVIVED-BCIS2 Trial</h5>
                    <p class="text-xs text-secondary mb-2">PCI + OMT vs OMT alone in ischemic LV dysfunction (LVEF ≤35%)</p>
                    <p class="text-sm">No reduction in death or HF hospitalization with PCI</p>
                  </div>
                  <div class="bg-white p-4 rounded-lg">
                    <h5 class="font-semibold text-sm mb-2">ISCHEMIA-EXTEND</h5>
                    <p class="text-xs text-secondary mb-2">Long-term follow-up of ISCHEMIA trial cohorts</p>
                    <p class="text-sm">No mortality difference between invasive vs conservative strategies</p>
                  </div>
                </div>
              </div>
            </div>
          </div>

          <div id="trials-anoca" class="mt-12 bg-gradient-to-r from-indigo-50 to-purple-50 p-8 rounded-xl">
            <h3 class="section-title text-xl text-indigo-700 mb-6 flex items-center">
              <i class="fas fa-microscope text-indigo-600 mr-3"></i>
              5.3 ANOCA/INOCA Trials
            </h3>
            <div class="grid md:grid-cols-3 gap-6">
              <div class="bg-white p-4 rounded-lg">
                <h4 class="font-semibold text-sm mb-2">CorMicA Trial</h4>
                <p class="text-xs text-secondary">Stratified medical therapy based on invasive coronary function testing improved angina symptoms</p>
              </div>
              <div class="bg-white p-4 rounded-lg">
                <h4 class="font-semibold text-sm mb-2">WARRIOR Trial</h4>
                <p class="text-xs text-secondary">Intensive guideline-based cardioprotective regimen vs usual care in women with ischemia, no obstructive CAD</p>
              </div>
              <div class="bg-white p-4 rounded-lg">
                <h4 class="font-semibold text-sm mb-2">PRIZE Trial</h4>
                <p class="text-xs text-secondary">Zibotentan (endothelin receptor antagonist) in patients with microvascular angina</p>
              </div>
            </div>
          </div>
        </div>
      </section>

      <div class="section-divider"></div>

      <section id="tables" class="py-16 bg-slate-50">
        <div class="max-w-6xl mx-auto px-8">
          <h2 class="section-title text-4xl text-primary mb-8">6. Quick Reference Tables</h2>

          <div id="tables-comparison" class="bg-white rounded-xl p-8 shadow-sm mb-8">
            <h3 class="section-title text-xl mb-6">6.1 Comparison of Key Recommendations - ESC 2024 vs. ACC/AHA 2023 Guidelines</h3>
            <div class="overflow-x-auto">
              <table class="w-full text-sm">
                <thead class="bg-slate-100">
                  <tr>
                    <th class="text-left p-3 font-semibold">Aspect of Management</th>
                    <th class="text-left p-3 font-semibold">2023 AHA/ACC CCD Guideline</th>
                    <th class="text-left p-3 font-semibold">COR (AHA/ACC)</th>
                    <th class="text-left p-3 font-semibold">2024 ESC CCS Guideline</th>
                    <th class="text-left p-3 font-semibold">COR (ESC)</th>
                  </tr>
                </thead>
                <tbody class="divide-y divide-slate-200">
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">Terminology</td>
                    <td class="p-3">"Chronic Coronary Disease (CCD)"</td>
                    <td class="p-3">N/A</td>
                    <td class="p-3">"Chronic Coronary Syndromes (CCS)"; emphasizes structural/functional alterations</td>
                    <td class="p-3">N/A</td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">Pretest Likelihood</td>
                    <td class="p-3">No specific model recommended</td>
                    <td class="p-3">N/A</td>
                    <td class="p-3">Risk factor-weighted clinical likelihood (RF-CL) model</td>
                    <td class="p-3"><span class="evidence-level class-i">I B</span></td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">Antiplatelet Therapy</td>
                    <td class="p-3">Low-dose aspirin (75-100mg) recommended</td>
                    <td class="p-3"><span class="evidence-level class-i">I A</span></td>
                    <td class="p-3">Clopidogrel monotherapy Class IA for post-MI/PCI patients</td>
                    <td class="p-3"><span class="evidence-level class-i">I A</span></td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">Lipid-Lowering</td>
                    <td class="p-3">High-intensity statin; mod-intensity if contraindicated</td>
                    <td class="p-3"><span class="evidence-level class-i">I A</span></td>
                    <td class="p-3">LDL-C &lt;1.4 mmol/L and ≥50% reduction</td>
                    <td class="p-3"><span class="evidence-level class-i">I A</span></td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">SGLT2i/GLP-1RA</td>
                    <td class="p-3">Recommended in T2DM for MACE reduction</td>
                    <td class="p-3"><span class="evidence-level class-i">I A</span></td>
                    <td class="p-3">Recommended in T2DM; GLP-1RA considered in obese without T2DM</td>
                    <td class="p-3"><span class="evidence-level class-i">I A</span></td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">Multidisciplinary Team</td>
                    <td class="p-3">Recommended for improved outcomes</td>
                    <td class="p-3"><span class="evidence-level class-i">I A</span></td>
                    <td class="p-3">Multidisciplinary behavioral approaches recommended</td>
                    <td class="p-3"><span class="evidence-level class-i">I A</span></td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>

          <div id="tables-trials" class="bg-white rounded-xl p-8 shadow-sm mb-8">
            <h3 class="section-title text-xl mb-6">6.2 Summary of Recent Major Clinical Trials in CCS (2022-2025)</h3>
            <div class="overflow-x-auto">
              <table class="w-full text-sm">
                <thead class="bg-slate-100">
                  <tr>
                    <th class="text-left p-3 font-semibold">Trial</th>
                    <th class="text-left p-3 font-semibold">Population</th>
                    <th class="text-left p-3 font-semibold">Intervention</th>
                    <th class="text-left p-3 font-semibold">Key Findings</th>
                    <th class="text-left p-3 font-semibold">Impact</th>
                  </tr>
                </thead>
                <tbody class="divide-y divide-slate-200">
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">HOST-EXAM</td>
                    <td class="p-3">Post-PCI patients</td>
                    <td class="p-3">Clopidogrel vs Aspirin</td>
                    <td class="p-3">Clopidogrel superior (5.7% vs 7.7%, HR 0.73)</td>
                    <td class="p-3">Supported ESC Class IA for clopidogrel</td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">Master-DAPT</td>
                    <td class="p-3">High bleeding risk post-PCI</td>
                    <td class="p-3">1 vs ≥6 months DAPT</td>
                    <td class="p-3">Abbreviated DAPT non-inferior, superior for bleeding</td>
                    <td class="p-3">Reinforced shorter DAPT in HBR</td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">LoDoCo2</td>
                    <td class="p-3">Chronic Coronary Disease</td>
                    <td class="p-3">Colchicine 0.5mg vs Placebo</td>
                    <td class="p-3">31% reduction in composite CV endpoint</td>
                    <td class="p-3">ESC Class IIbA for colchicine</td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">SELECT</td>
                    <td class="p-3">Obese with CVD, no diabetes</td>
                    <td class="p-3">Semaglutide vs Placebo</td>
                    <td class="p-3">20% reduction in MACE</td>
                    <td class="p-3">ESC Class IIaB for GLP-1RA in obesity</td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">ORBITA-2</td>
                    <td class="p-3">Stable angina, no antianginals</td>
                    <td class="p-3">PCI vs Sham</td>
                    <td class="p-3">PCI improved angina symptoms</td>
                    <td class="p-3">Reinforced PCI for symptom relief</td>
                  </tr>
                  <tr class="hover:bg-slate-50">
                    <td class="p-3 font-medium">REVIVED-BCIS2</td>
                    <td class="p-3">Ischemic LV dysfunction</td>
                    <td class="p-3">PCI + OMT vs OMT</td>
                    <td class="p-3">No reduction in death/HF hospitalization</td>
                    <td class="p-3">Emphasized OMT as primary strategy</td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>

          <div id="tables-diagnostic" class="bg-white rounded-xl p-8 shadow-sm">
            <h3 class="section-title text-xl mb-6">6.3 ESC 2024 Diagnostic Approach for Suspected CCS</h3>
            <div class="grid lg:grid-cols-2 gap-8">
              <div class="space-y-4">
                <div class="bg-blue-50 p-4 rounded-lg border-l-4 border-blue-500">
                  <h4 class="font-semibold mb-2">Step 1: General Clinical Examination</h4>
                  <p class="text-sm">Detailed symptom assessment, physical examination, 12-lead ECG, basic blood tests</p>
                </div>
                <div class="bg-purple-50 p-4 rounded-lg border-l-4 border-purple-500">
                  <h4 class="font-semibold mb-2">Step 2: Pre-test Likelihood Assessment</h4>
                  <p class="text-sm">TTE, RF-CL model, exercise ECG in selected patients</p>
                </div>
              </div>
              <div class="space-y-4">
                <div class="bg-green-50 p-4 rounded-lg border-l-4 border-green-500">
                  <h4 class="font-semibold mb-2">Step 3: Confirming Diagnosis</h4>
                  <p class="text-sm">CCTA for low-intermediate PCL, functional imaging, invasive tests as needed</p>
                </div>
                <div class="bg-amber-50 p-4 rounded-lg border-l-4 border-amber-500">
                  <h4 class="font-semibold mb-2">Step 4: Initial Therapy & Follow-up</h4>
                  <p class="text-sm">GDMT optimization, revascularization for persistent symptoms</p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <footer class="bg-primary text-white py-12">
        <div class="max-w-6xl mx-auto px-8">
          <div class="grid md:grid-cols-2 gap-8">
            <div>
              <h3 class="section-title text-xl mb-4">Key References</h3>
              <div class="space-y-2 text-sm">
                <p>• 2024 ESC Guidelines for Chronic Coronary Syndromes</p>
                <p>• 2023 ACC/AHA Guideline for Chronic Coronary Disease</p>
                <p>• Braunwald's Textbook of Cardiovascular Medicine</p>
                <p>• Major clinical trials: ISCHEMIA, ORBITA-2, LoDoCo2, SELECT</p>
              </div>
            </div>
            <div>
              <h3 class="section-title text-xl mb-4">Clinical Applications</h3>
              <div class="space-y-2 text-sm">
                <p>• Individualized risk assessment using RF-CL model</p>
                <p>• Clopidogrel preference in post-MI/PCI patients</p>
                <p>• Aggressive LDL-C targets with combination therapy</p>
                <p>• Heart Team approach for revascularization decisions</p>
              </div>
            </div>
          </div>
          <div class="border-t border-blue-400 mt-8 pt-8 text-center text-sm">
            <p>This comprehensive review synthesizes current evidence for CCS management based on the latest international guidelines and clinical trial data.</p>
          </div>
        </div>
      </footer>
    </div>

    <script>
        // Initialize Vanta.js background
        VANTA.NET({
            el: "#vanta-bg",
            mouseControls: true,
            touchControls: true,
            gyroControls: false,
            minHeight: 200.00,
            minWidth: 200.00,
            scale: 1.00,
            scaleMobile: 1.00,
            color: 0x1e40af,
            backgroundColor: 0x0f172a,
            points: 8.00,
            maxDistance: 20.00,
            spacing: 16.00
        });

        // Table of Contents functionality (from pediatric myocarditis)
        function toggleTOC() {
            const toc = document.getElementById('toc');
            toc.classList.toggle('open');
        }

        // Smooth scrolling for TOC links (from pediatric myocarditis)
        document.querySelectorAll('.toc-link').forEach(link => {
            link.addEventListener('click', function(e) {
                e.preventDefault();
                const targetId = this.getAttribute('href').substring(1);
                const targetElement = document.getElementById(targetId);
                if (targetElement) {
                    targetElement.scrollIntoView({
                        behavior: 'smooth',
                        block: 'start'
                    });
                }

                // Close TOC on mobile after clicking a link
                if (window.innerWidth <= 1024) {
                    document.getElementById('toc').classList.remove('open');
                }
            });
        });

        // Active TOC link highlighting (from pediatric myocarditis, adapted for new structure)
        function updateActiveTOCLink() {
            const sections = document.querySelectorAll('section[id], div[id]'); /* Added div[id] to capture sub-sections */
            const tocLinks = document.querySelectorAll('.toc-link');
            
            let currentSection = '';
            
            sections.forEach(section => {
                const rect = section.getBoundingClientRect();
                // A section is "active" if its top is visible and it hasn't scrolled past completely
                // Adjusted threshold for better responsiveness
                if (rect.top <= window.innerHeight * 0.2 && rect.bottom >= window.innerHeight * 0.2) {
                    currentSection = section.id;
                }
            });
            
            tocLinks.forEach(link => {
                link.classList.remove('active');
                if (link.getAttribute('href') === '#' + currentSection) {
                    link.classList.add('active');
                }
            });
        }

        // Update active TOC link on scroll
        window.addEventListener('scroll', updateActiveTOCLink);
        
        // Close TOC when clicking outside on mobile (from pediatric myocarditis)
        document.addEventListener('click', function(event) {
            const toc = document.getElementById('toc');
            const toggleButton = document.querySelector('.toggle-toc');
            
            if (window.innerWidth <= 1024 && 
                toc.classList.contains('open') && 
                !toc.contains(event.target) && 
                !toggleButton.contains(event.target)) {
                toc.classList.remove('open');
            }
        });

        // Initialize (from pediatric myocarditis)
        updateActiveTOCLink();
    </script>
  </body>

</html>